Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 12
Submit an article Journal homepage
727
Views
53
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

Ruben Niesvizky Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of MedicineCorrespondence[email protected]
,
Déborah Martínez-Baños Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Jessica Jalbrzikowski Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Paul Christos Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University and the New York Presbyterian Hospital-Cornell Medical Center, New York, NY, USA
,
Jessica Furst Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Maria De Sancho Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Tomer Mark Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Roger Pearse Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Madhu Mazumdar Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University and the New York Presbyterian Hospital-Cornell Medical Center, New York, NY, USA
,
Faiza Zafar Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
Karen Pekle Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
John Leonard Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
,
David Jayabalan Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
&
Morton Coleman Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine
 show all
Pages 2330-2337 | Received 11 Jul 2007, Accepted 23 Aug 2007, Published online: 01 Jul 2009

Citations (53)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Sylvain Garciaz, Diane Coso, Jean-Marc Schiano de Colella & Réda Bouabdallah. (2016) Lenalidomide for the treatment of B-cell lymphoma. Expert Opinion on Investigational Drugs 25:9, pages 1103-1116.
Read now
Peter H Wiernik. (2013) Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 14:4, pages 475-488.
Read now
Eileen M Boyle, Guillemette Fouquet, Salomon Manier, Jordan Gauthier, Marie Pierre Noel, Claire Borie, Thierry Facon, Ismail Elalamy & Xavier Leleu. (2012) Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Review of Hematology 5:6, pages 619-629.
Read now
Gabriela Cesarman-Maus, Esteban Braggio & Rafael Fonseca. (2012) Thrombosis in multiple myeloma (MM). Hematology 17:sup1, pages s177-s180.
Read now
Patrizia Falco, Federica Cavallo, Alessandra Larocca, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro & Antonio Palumbo. (2008) Lenalidomide and its role in the management of multiple myeloma. Expert Review of Anticancer Therapy 8:6, pages 865-874.
Read now
Ruben Niesvizky & Déborah M. Martínez-Baños. (2008) Aspirin as thromboprophylaxis in myeloma. Leukemia & Lymphoma 49:8, pages 1646-1647.
Read now
Semra Paydas. (2008) Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs. Leukemia & Lymphoma 49:8, pages 1644-1645.
Read now
Donna E. Reece, Heather A. Leitch, Harold Atkins, Michael Voralia, Leah A. Canning, Richard LeBlanc, Andrew R. Belch, Darrell White & Michael J. Kovacs. (2008) Treatment of relapsed and refractory myeloma. Leukemia & Lymphoma 49:8, pages 1470-1485.
Read now
Efstathios Kastritis & Meletios Dimopoulos. (2007) How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia & Lymphoma 48:12, pages 2295-2297.
Read now

Articles from other publishers (44)

Vignesh Narayan R & Tarun Narang. (2022) Comment on: ‘The role of thalidomide in dermatology’. Clinical and Experimental Dermatology 47:5, pages 982-983.
Crossref
Marco SANTORO, Alessandra ROMANO, Salvatrice MANCUSO, Sergio SIRAGUSA, Francesco DI RAIMONDO, Giovanni MARTINELLI & Claudio CERCHIONE. (2021) Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Medica 63:1.
Crossref
Anne WS Rutjes, Ettore Porreca, Matteo Candeloro, Emanuele Valeriani & Marcello Di Nisio. (2020) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2020:12.
Crossref
Valeria Calafiore, Silvia Giamporcaro, Concetta Conticello, Alessandra Romano, Marina Parisi, Gaetano Giuffrida, Daniele Tibullo, Francesco Di Raimondo & Salvatore Santo Signorelli. (2020) A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. Journal of Clinical Medicine 9:9, pages 2876.
Crossref
Fehaid Alanazi, Faith A.A. Kwa, Genia Burchall & Denise E. Jackson. (2020) New generation drugs for treatment of multiple myeloma. Drug Discovery Today 25:2, pages 367-379.
Crossref
Ranjit Nair & Krina Patel. 2020. Oncologic Critical Care. Oncologic Critical Care 1513 1530 .
Ranjit Nair & Krina Patel. 2019. Oncologic Critical Care. Oncologic Critical Care 1 18 .
Giacomo Zoppellaro, Nicola Veronese, Serena Granziera, Laura Gobbi, Brendon Stubbs & Alexander T. Cohen. (2018) Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Seminars in Hematology 55:4, pages 182-184.
Crossref
Pashtoon Murtaza Kasi & Grzegorsz S. Nowakowski. 2018. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas 73 83 .
Aurore Palmaro, Marie-Eve Rougé-Bugat, Martin Gauthier, Fabien Despas, Guillaume Moulis & Maryse Lapeyre-Mestre. (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiology and Drug Safety 26:5, pages 578-586.
Crossref
Maria T. De Sancho & Jacob H. Rand. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 11 .
Jiang-Hua Ding, Li-Ya Yuan & Guo-An Chen. (2017) Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Oncology Letters 13:2, pages 647-654.
Crossref
Marcello Di Nisio, Ettore Porreca, Matteo Candeloro, Michele De Tursi, Ilaria Russi & Anne WS Rutjes. (2016) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews.
Crossref
José Ramiro Espinoza-Zamora, César Miguel Portilla-Espinosa, Juan Rafael Labardini-Méndez, Eduardo Cervera, Ruben Niesvisky & Luis F. Oñate-Ocaña. (2015) Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Annals of Hematology 94:6, pages 1017-1024.
Crossref
Jiang-hua Ding, Li-ya Yuan, Rui-Bin Huang & Guo-an Chen. (2014) Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. European Journal of Haematology 93:4, pages 329-339.
Crossref
Marcello Di Nisio, Ettore Porreca, Hans-Martin Otten & Anne WS Rutjes. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jacek Treliński, Małgorzata Misiewicz, Marta Robak, Piotr Smolewski & Krzysztof Chojnowski. (2014) Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thrombosis Research 133:4, pages 667-670.
Crossref
Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung-Soo Yoon, Je-Jung Lee, Jae-Yong Kwak, Hun-Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung-Hyun Kim, Yeung-Chul Mun, Jin Seok Kim, Hyeon-Seok Eom, Deog-Yeon Jo, Hyun Jung Jun, Ki-Hwan Kim, Jeong-Ok Lee, Jae Hoon Lee & Chang-Ki Min. (2013) Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients. Annals of Hematology 93:1, pages 113-121.
Crossref
Garrett B Aikens, Michael P Rivey & Carly J Hansen. (2013) Primary Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients. Annals of Pharmacotherapy 47:2, pages 198-209.
Crossref
P. Casassus. (2013) Traitement du myélome multiple. EMC - Hématologie 8:1, pages 1-16.
Crossref
Xavier Leleu, Philippe Rodon, Cyrille Hulin, Laurent Daley, Charles Dauriac, Maya Hacini, Olivier Decaux, Jean-Claude Eisemann, Olivier Fitoussi, Bruno Lioure, Laurent Voillat, Borhane Slama, Ahmad Al Jijakli, Riad Benramdane, Carinne Chaleteix, Régis Costello, Antoine Thyss, Claire Mathiot, Boyle Eileen, Frédéric Maloisel, Anne-Marie Stoppa, Brigitte Kolb, Mauricette Michallet, Anne Lamblin, Patrick Natta, Thierry Facon, Ismail Elalamy, Jean-Paul Fermand & Philippe Moreau. (2017) MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thrombosis and Haemostasis 110:10, pages 844-851.
Crossref
Marliese ALEXANDER, Sue KIRSA & James D MELLOR. (2012) Thalidomide thromboprophylaxis in multiple myeloma: A review of current evidence. Asia-Pacific Journal of Clinical Oncology 8:4, pages 319-324.
Crossref
Marta Robak, Jacek Treliński & Krzysztof Chojnowski. (2012) Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Medical Oncology 29:5, pages 3574-3580.
Crossref
Antonio Palumbo & Carmela Palladino. (2012) Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Therapeutic Advances in Drug Safety 3:5, pages 255-266.
Crossref
Xavier Leleu. (2012) Thrombosis in Myeloma treated with IMiDs. Thrombosis Research 130, pages S63-S65.
Crossref
Andrzej Jakubowiak. (2012) Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives. Seminars in Hematology 49, pages S16-S32.
Crossref
G Cesarman-Maus, E Braggio, H Maldonado & R Fonseca. (2012) Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia 26:7, pages 1671-1674.
Crossref
Gordon F. Rushworth, Stephen J. Leslie, Peter Forsyth & Claire Vincent. (2012) Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Therapeutic Advances in Drug Safety 3:3, pages 115-122.
Crossref
Cristina João, Alfredo Figueiredo & Helena Figueira Martins. (2012) Advantageous use of lenalidomide in multiple myeloma. Current Opinion in Oncology 24:Supplement 2, pages S13-S20.
Crossref
Alessandra LaroccaFederica CavalloSara BringhenFrancesco Di RaimondoAnna FalangaAndrea EvangelistaMaide CavalliAnfisa StanevskyPaolo CorradiniSara PezzattiFrancesca PatriarcaMichele CavoJacopo PeccatoriLucio CatalanoAngelo Michele CarellaAnna Maria CafroAgostina SiniscalchiClaudia CrippaMaria Teresa PetrucciDina Ben Yehuda, Eloise Beggiato, Tommaso Caravita Di TorittoMario BoccadoroArnon NaglerAntonio Palumbo. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119:4, pages 933-939.
Crossref
Sigurdur Yngvi Kristinsson, Magnus Björkholm, Sam Schulman & Ola Landgren. (2011) Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology 48:1, pages 46-54.
Crossref
Sigurdur Yngvi Kristinsson. (2010) Thrombosis in Multiple Myeloma. Hematology 2010:1, pages 437-444.
Crossref
Paul G. RichardsonEdie WellerSagar LonialAndrzej J. JakubowiakSundar JagannathNoopur S. RajeDavid E. AviganWanling XieIrene M. GhobrialRobert L. SchlossmanAmitabha MazumderNikhil C. MunshiDavid H. VesoleRobin JoyceJonathan L. KaufmanDeborah DossDiane L. WarrenLaura E. LundeSarah KasterCarol DeLaneyTeru HideshimaConstantine S. MitsiadesRobert Knight, Dixie-Lee Esseltine & Kenneth C. Anderson. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:5, pages 679-686.
Crossref
María-Victoria Mateos. (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treatment Reviews 36, pages S24-S32.
Crossref
Anna FalangaMarina Marchetti. (2009) Venous Thromboembolism in the Hematologic Malignancies. Journal of Clinical Oncology 27:29, pages 4848-4857.
Crossref
Edward N. Libby & Agnes Y. Lee. 2009. New Therapeutic Agents in Thrombosis and Thrombolysis. New Therapeutic Agents in Thrombosis and Thrombolysis 221 236 .
Charles Eby. (2009) Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. British Journal of Haematology 145:2, pages 151-163.
Crossref
Peter H. Wiernik. (2008) Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology 10:1-2, pages 1-15.
Crossref
Tomer Mark, Ruben Niesvizky & Morton Coleman. (2009) Novel agents in myeloma: An exciting saga. Cancer 115:2, pages 236-242.
Crossref
Christine VolkUlrike Klein. (2009) Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. Clinical Medicine. Therapeutics 1, pages CMT.S2295.
Crossref
T. C. M. Morris, P. J. Kettle, M. Drake, F. C. G. Jones, D. R. Hull, K. Boyd, A. Morrison, P. Clarke, P. O’Reilly & J. Quinn. (2008) Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British Journal of Haematology 143:3, pages 349-354.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Ruben Niesvizky, David S. Jayabalan, Paul J. Christos, Jessica R. Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N. Pearse, Faiza Zafar, Karen Pekle, April LaRow, Richard Lent, Tomer Mark, Hearn J. Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael W. Schuster, Susan Mathew, John P. Leonard, Madhu Mazumdar, Selina Chen-Kiang & Morton Coleman. (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood 111:3, pages 1101-1109.
Crossref
Alessandro Corso & Silvia Mangiacavalli. (2008) The place of thalidomide in the treatment of multiple myeloma. Oncology Reviews 1:4, pages 205-214.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.